Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (929)	10/20/1999 8:09:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1386

Lets see if PARS BOL can capitalize on this. competition gets a recall November 1, 1999 FORT WORTH, Texas ? Alcon Laboratories Inc. and its affiliate Falcon Pharmaceuticals Ltd. recalled its diclofenac sodium ophthalmic solution 0.1%, a topical ophthalmic non steroidal anti-inflammatory drug (NSAID), in the wake of reports of corneal perforations in patients using the drug. ?We are taking this action because of additional concern with reports of adverse events following aggressive use of topical ophthalmic NSAIDs,? said Stella Robertson, PhD, vice president of pharmaceutical products research and development. ?In earlier written communication to eye care professionals, Alcon emphasized the importance of using topical NSAIDs according to labeled instructions,? the company stated in a press release. ?Our data show that when used as labeled, Falcon diclofenac is safe and effective,? Dr. Robertson added. ?However, we have become aware that off-label use is still prevalent.? These adverse events appear to be more prevalent in patients with corneal problems, including those with dry eye or corneal epithelial defects. The company said that consulting physicians, including members of the American Society of Cataract and Refractive Surgery, recommended that Alcon remove diclofenac from the market.